Curasight (the Company) is a pioneer in the field of exploiting the Positron Emissions Tomography (PET) imaging platform targeting the receptor uPAR, which is a known biomarker of cancer aggressiveness, to be used for improved diagnosis in multiple types of cancer. This patent application relates to Curasight's diagnostic technology uTRACE® (imaging agent [64]Cu-DOTA-AE105) and uses thereof until 2040.

Curasight has developed a novel radiopharmaceutical platform uTRACE[®] for improved diagnose, risk stratification and treatment monitoring for cancer patients based on uPAR PET imaging within different cancer indications.  Together with uTREAT[®], the combination is known as uPAR Theranostics - the combination of therapy and diagnostics.

"For Curasight the addition of this granted US patent - based on the [64]Cu-imaging agent is an important milestone in the development of uTRACE[®] as a comprehensive diagnostic platform for uses in many cancer indications. Together with the already issued patent for uTRACE[®] based on the [68]Ga imaging agent, the uTRACE® platform now consist of two imaging agents both targeting uPAR but with different characteristics. The addition of a second compound is of great importance for our commercial strategy and means that we will have a strong position in the North American market - especially for healthcare providers who prefer to use Cu (copper) as the radioactive isotopes," says CEO Ulrich Krasilnikoff.